Scrutiny Continues to Grow Around the Cost of Specialty Drugs

Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.

Related Content:

InterviewsReimbursementSpecialty Pharmacy

Treatment with Ofatumumab Increases Number of Patients Who Achieve No Evidence of Disease Activity for MS

Bringing Oncology Pharmacy Leaders, Payers Together to Address Unmet Educational Needs in the Field

Oncology Overview: Sonidegib (Odomzo) for Locally Advanced Basal Cell Carcinoma